• Austria
• Belgium
• Denmark
• Finland
• France
• Germany
• Italy
• Netherlands
• Spain
• Switzerland
• USA

1. A polynucleotide comprising i) a nucleotide sequence encoding a specific chimeric antigen receptor (CAR) and ii) a promoter from the Wiskott-Aldrich syndrome locus or a fragment of said promoter comprising SEQ ID NO 2 or a nucleotide sequence having at least 70% identity with SEQ. ID NO 2, wherein said promoter is operably linked to the nucleotide sequence encoding the CAR in order to drive the expression of the chimeric antigen receptor, and wherein the CAR comprises at least one extracellular ligand binding domain, a transmembrane domain and at least one intracellular signalling domain.

2. The polynucleotide of claim 1, wherein the promoter comprises SEQ ID NO 1 or a nucleotide sequence having at least 70% identity with SEQ ID NO 1.

3. The polynucleotide of claim 1, wherein the promoter is SEQ ID NO 1.

4. An expression vector comprising the nucleic acid of any of claims 1 to 3.

5. The expression vector of claim 4, wherein said expression vector is a viral vector.

6. The viral vector of claim 5, wherein said viral vector is a lentiviral vector.

7. Immune cells expressing at the cell surface membrane a specific chimeric antigen receptor comprising at least one extracellular ligand binding domain and at least one intracellular signalling domain wherein said Immune cells are transduced with theviral expression vector of any of claims 5 to 6.

8. Immune cells expressing at the cell surface membrane a specific chimeric antigen receptor comprising at least one extracellular ligand binding domain and at least one intracellular signalling domain wherein said chimeric antigen receptor is expressed by the expression vector of claim 4.

9. The immune cells according to any one of claims 7 to 8 derived from inflammatory T- lymphocytes, cytotoxic T-lymphocytes, regulatory T- lymphocytes or helper T- lymphocytes.

10. The immune cells according to any one of claims 7 to 9, wherein the cells are recovered from donors.

11. The immune cells according to any one of claims 7 to 8, wherein the cells are recovered from patients.

12. The immune cells according to any one of claims 7 to llfor use in therapy.

13. The immune cells according to any one of claims 7 to 11 for use in the treatment of cancer, such as neoplasias, B-cell neoplasias, lymphoma or leukaemia, or multiple myeloma.